Company / Operating Cash Flow
CAPRICOR THERAPEUTICS, INC. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$69.8M
FY2025
5-year range
-$69.8M / $4.9M
FY2021-FY2025
Trend
-74.5%
vs FY2024
Sector context
#105 of 216
Health Care
What the data says
At -$70M, CAPRICOR THERAPEUTICS, INC.'s operating cash flow ranks #105 of 216 in the Health Care sector. Operating Cash Flow has declined for 3 consecutive years, from $5M in FY2022 to -$70M in FY2025.
Based on SEC 10-K filings.
-$70M in FY2025.
Declined from -$26M to -$70M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#105 of 216 in Health CareTop 49% of 216This company -$69.8M Sector average $658.7M
▼
-110.6% below sector average
Key checks
Key Insights
- CAPRICOR THERAPEUTICS, INC.'s operating cash flow has declined for 3 consecutive years.
- In FY2025, operating cash flow decreased 74.5% year-over-year.
- Ranks #105 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$69.8M | -74.5% |
| FY2024 | -$40.0M | -56.3% |
| FY2023 | -$25.6M | -620.6% |
| FY2022 | $4.9M | +129.2% |
| FY2021 | -$16.8M | -67.2% |
| FY2020 | -$10.1M | +27.5% |
| FY2019 | -$13.9M | +0.0% |
| FY2018 | -$13.9M | +2.6% |
| FY2017 | -$14.2M | +1.5% |
| FY2016 | -$14.5M | -33.6% |
As of FY2025 · SEC 10-K · Updated Jul 4, 2026